FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308142145> ?p ?o ?g. }

• W4308142145 endingPage "A803" @default.
• W4308142145 startingPage "A802" @default.
• W4308142145 abstract "Abstract Background Adults with chronic hypoparathyroidism managed with conventional therapy (calcitriol, alfacalcidol, and oral calcium) generally report a reduced quality of life (QoL) and remain at risk for long-term complications from abnormal calcium and phosphate metabolism. The PaTHway trial assessed the efficacy and safety of TransCon PTH at Week 26. Methods PaTHway was a double-blind, placebo-controlled 26-week trial with 3: 1 randomization to TransCon PTH 18 mcg/d or placebo, co-administered with conventional therapy. The composite primary efficacy endpoint was the proportion of participants at Week 26 who achieved: serum calcium levels in the normal range (8.3–10.6 mg/dL), independence from conventional therapy defined as requiring no active vitamin D and ≤600 mg/day of calcium supplementation, and no increase in prescribed study drug over 4 weeks prior to Week 26. Key secondary endpoints included Hypoparathyroidism Patient Experience Scale (HPES) domain scores and 36-Item Short Form Survey (SF-36) subscale scores. Results 82 participants were dosed (78% female, mean age 49 years). 79 completed treatment through Week 26. 79% (48/61) of participants randomized to TransCon PTH met the composite primary efficacy endpoint, compared to 5% (1/21) in the placebo group (p &lt;0.0001). 93% (57/61) participants treated with TransCon PTH achieved independence from conventional therapy. At baseline, mean serum calcium was 8.8 and 8.7 mg/dL for TransCon PTH and placebo respectively; 8.9 mg/dL and 8.2 mg/dL at Week 26, respectively. For TransCon PTH, mean urine calcium decreased significantly from 390 mg/24-hour at baseline to 220 mg/24-hour (normal range &lt;250 mg/24-hour) at Week 26 compared to 329 mg/24-hour at baseline to 292 mg/24-hour at Week 26 for placebo. TransCon PTH therapy demonstrated a significant improvement in HPES-Symptom domain scores − Physical (p = 0.0038) and Cognitive (p = 0.0055), HPES-Impact domain scores − Physical Functioning (p = 0.0046) and Daily Life (p = 0.0061), and SF-36 Physical Functioning subscale score (p = 0.0347) compared to placebo. Overall, TransCon PTH was well-tolerated. The majority of adverse events (AE) were mild or moderate in severity. The most commonly reported study drug-related AEs were injection site reactions, hypercalcemia, and headaches. No study drug-related AEs led to withdrawal from the study. Conclusions In the PaTHway phase 3 trial, 79% of participants on TransCon PTH therapy (versus 5% on placebo) were able to achieve independence from conventional therapy while maintaining normocalcemia at Week 26. Uniquely, TransCon PTH therapy decreased and normalized 24-hour urine calcium excretion and significantly improved QoL (symptom burden and impact) from baseline compared to placebo. These data suggest the potential for TransCon PTH to improve clinical outcomes and QoL compared to current conventional therapy. Presentation: Tuesday, June 14, 2022 10:45 a.m. - 11:00 a.m." @default.
• W4308142145 created "2022-11-08" @default.
• W4308142145 creator A5063080270 @default.
• W4308142145 date "2022-11-01" @default.
• W4308142145 modified "2023-09-24" @default.
• W4308142145 title "OR29-5 Phase 3 PaTHway Trial: Participants Treated With TransCon PTH Achieved Independence From Conventional Therapy While Maintaining Normal Serum Calcium" @default.
• W4308142145 doi "https://doi.org/10.1210/jendso/bvac150.1661" @default.
• W4308142145 hasPublicationYear "2022" @default.
• W4308142145 type Work @default.
• W4308142145 citedByCount "1" @default.
• W4308142145 countsByYear W43081421452022 @default.
• W4308142145 crossrefType "journal-article" @default.
• W4308142145 hasAuthorship W4308142145A5063080270 @default.
• W4308142145 hasBestOaLocation W43081421451 @default.
• W4308142145 hasConcept C124490489 @default.
• W4308142145 hasConcept C126322002 @default.
• W4308142145 hasConcept C126894567 @default.
• W4308142145 hasConcept C134018914 @default.
• W4308142145 hasConcept C142724271 @default.
• W4308142145 hasConcept C168563851 @default.
• W4308142145 hasConcept C203092338 @default.
• W4308142145 hasConcept C204243189 @default.
• W4308142145 hasConcept C204787440 @default.
• W4308142145 hasConcept C27081682 @default.
• W4308142145 hasConcept C2776079296 @default.
• W4308142145 hasConcept C2776541429 @default.
• W4308142145 hasConcept C2776886416 @default.
• W4308142145 hasConcept C2779126354 @default.
• W4308142145 hasConcept C2781208988 @default.
• W4308142145 hasConcept C519063684 @default.
• W4308142145 hasConcept C71924100 @default.
• W4308142145 hasConcept C90924648 @default.
• W4308142145 hasConceptScore W4308142145C124490489 @default.
• W4308142145 hasConceptScore W4308142145C126322002 @default.
• W4308142145 hasConceptScore W4308142145C126894567 @default.
• W4308142145 hasConceptScore W4308142145C134018914 @default.
• W4308142145 hasConceptScore W4308142145C142724271 @default.
• W4308142145 hasConceptScore W4308142145C168563851 @default.
• W4308142145 hasConceptScore W4308142145C203092338 @default.
• W4308142145 hasConceptScore W4308142145C204243189 @default.
• W4308142145 hasConceptScore W4308142145C204787440 @default.
• W4308142145 hasConceptScore W4308142145C27081682 @default.
• W4308142145 hasConceptScore W4308142145C2776079296 @default.
• W4308142145 hasConceptScore W4308142145C2776541429 @default.
• W4308142145 hasConceptScore W4308142145C2776886416 @default.
• W4308142145 hasConceptScore W4308142145C2779126354 @default.
• W4308142145 hasConceptScore W4308142145C2781208988 @default.
• W4308142145 hasConceptScore W4308142145C519063684 @default.
• W4308142145 hasConceptScore W4308142145C71924100 @default.
• W4308142145 hasConceptScore W4308142145C90924648 @default.
• W4308142145 hasIssue "Supplement_1" @default.
• W4308142145 hasLocation W43081421451 @default.
• W4308142145 hasLocation W43081421452 @default.
• W4308142145 hasOpenAccess W4308142145 @default.
• W4308142145 hasPrimaryLocation W43081421451 @default.
• W4308142145 hasRelatedWork W1974087872 @default.
• W4308142145 hasRelatedWork W1990422519 @default.
• W4308142145 hasRelatedWork W1999545086 @default.
• W4308142145 hasRelatedWork W2013152947 @default.
• W4308142145 hasRelatedWork W2064236298 @default.
• W4308142145 hasRelatedWork W2067836013 @default.
• W4308142145 hasRelatedWork W2107597037 @default.
• W4308142145 hasRelatedWork W2107762597 @default.
• W4308142145 hasRelatedWork W2127828880 @default.
• W4308142145 hasRelatedWork W2162385374 @default.
• W4308142145 hasVolume "6" @default.
• W4308142145 isParatext "false" @default.
• W4308142145 isRetracted "false" @default.
• W4308142145 workType "article" @default.